PLX — Protalix BioTherapeutics, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-01-04.
Performance
Technicals
Others in Healthcare
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2025-12-19 | Bashan Dror PRESIDENT AND CEO | Open-market purchase | 56.0K | 1.81 | 101.4K |
| 2025-11-18 | Bar-Shalev Amos Director | Open-market sale | 168 | 1.87 | 314 |
| 2025-09-03 | Forster Eliot Director | Grant or award | 7.5K | — | — |
| 2025-09-03 | Ben Zvi Shmuel Director | Grant or award | 7.5K | — | — |
| 2025-09-03 | Melincoff Gwen A Director | Grant or award | 7.5K | — | — |
| 2025-09-03 | Schwartz Aharon Director | Grant or award | 7.5K | — | — |
| 2025-09-03 | Bar-Shalev Amos Director | Grant or award | 7.5K | — | — |
| 2025-09-03 | Elze Christian Director | Grant or award | 7.5K | — | — |
| 2025-09-03 | Boudes Pol F Director | Grant or award | 7.5K | — | — |
| 2025-09-03 | Naos Yaron Sr. VP, Operations | Grant or award | 25.0K | — | — |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| BlackRock, Inc. | 7.8M | 3.6M |
| MAK CAPITAL ONE LLC | 7.7M | 3.5M |
| RENAISSANCE TECHNOLOGIES LLC | 2.7M | 1.2M |
| STATE STREET CORP | 2.1M | 972.8K |
| NORTHERN TRUST CORP | 1.9M | 885.4K |
| GEODE CAPITAL MANAGEMENT, LLC | 1.9M | 865.3K |
| Stratos Wealth Partners, LTD. | 1.1M | 500.0K |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 938.5K | 432.5K |
| Prospera Financial Services Inc | 908.3K | 418.6K |
| Opaleye Management Inc. | 737.8K | 340.0K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Protalix Biotherapeutics, Inc. (PLX) filed form 8-K · 2026-08-12 · SEC EDGAR
Ask the AI about PLX
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →